In the attempt to assess a possible link between sphingolipid metabolism enzymes and the pathogenesis of MM, Watek and collaborators evaluated activity of acid sphingomyelinase (ASM), beta galactosidase, and beta glucosidase using a dry blood spot test in patients with different stages of MM disease. This evidence concerns the gene GLB1 and Miyoshi myopathy.